|
Synonyms: NT-0796 | NT0796
Compound class:
Synthetic organic
Comment: Ruvonoflast (NT-0796; Rezera, formerly NodThera) is an orally bioactive, selective, and brain-penetrant small-molecule inhibitor of NLRP3 inflammasome activity [1]. The anti-inflammatory action of ruvonoflast was proposed as a mechanism to reduce atherosclerotic cardiovascular risk [2], and potentially neuroinflammation.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| NT-0796 was advanced as a clinical candidate. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06129409 | Effects of NT-0796 in Obese Participants at Risk of Cardiovascular Disease | Phase 1/Phase 2 Interventional | NodThera Limited | 2 | |
| NCT07055516 | Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus | Phase 2 Interventional | Rezera (formerly NodThera Limited) | 2 | |
| NCT07220629 | Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2) | Phase 2 Interventional | Rezera (formerly NodThera Limited) | ||